Antibe Therapeutics Inc. Antibe Therapeutics Inc.

Antibe Therapeutics Inc.

ATE

Classificação em ações #31789
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Preço da ação
$0.21483059
Última sincronização: 2024-05-07
Valor de mercado
$11.13M
Variação (1 dia)
0.34%
Variação (1 ano)
-0.36%
País
CA
Negociar Antibe Therapeutics Inc. (ATE)

Categoria

Healthcare
Histórico de preços das ações de Antibe Therapeutics Inc. (ATE)
Preço de fecho mais alto: $0.22 em 2025-04-01

Preço de fecho mais baixo: $4.78 em 2014-10-01
Histórico de preços das ações da Antibe Therapeutics Inc. de 2014 a 2026
Desempenho anual do preço das ações
Ano Desempenho
2025 -0.02%
2024 -64.79%
2023 73.56%
2022 -33.35%
2021 -82.11%
2020 -6.13%
2019 60.42%
2018 70.25%
2017 -45.71%
2016 86.85%
2015 -71.73%
2014 0.00%
Preço das ações de empresas similares ou concorrentes
Empresa Preço da ação Variação 1a% País
$100.56 -21.41%
US
$93.07 -2.95%
IE
$297.13 -23.49%
US
$44.47 -57.18%
US
$46.87 -18.19%
DE